CBER’s Perspective on Advanced Manufacturing Celia M. Witten, Ph.D., M.D. Deputy Director Center for Biologics Evaluation and Research, FDA ISCMP 2018 London October 4 2018
Outline • CBER Overview • CBER Products/Manufacturing Challenges – Vaccines – Cells/Tissues/Gene Therapy • CBER engagements • 21st Century Cures • Summary
www.fda.gov
2
FDA Organization • Office of the Commissioner • Center for Biologics Evaluation and Research (CBER) – Office of Vaccines Research and Review (OVRR) – Office of Tissues and Advanced Therapies (OTAT) – Office of Blood Research and Review (OBRR) • Center for Drug Evaluation and Research (CDER) • Center for Devices and Radiological Health (CDRH) • National Center for Toxicological Research (NCTR) • Center for Food Safety and Applied Nutrition 9CFSAN) • Center for Veterinary Medicine (CVM) • Center for Tobacco Products (CTP) www.fda.gov
3
What Products Does CBER Regulate? • • • • • • • • www.fda.gov
Allergenics Blood Products Devices (subset including some IVDs) Gene Therapy Products Human Tissues and Cellular Products Vaccines (preventative and therapeutic) Xenotransplantation products Certain combination products 4
Advanced Manufacturing? • Why advanced manufacturing? Products may require complex manufacturing processes, advanced manufacturing may bring new tools to address: – Flexibility – Availability – Scalability – Cost • What do we mean by advanced manufacturing? Innovative technologies that could include: – Cell culture systems supporting large scale or rapid production – Enabling tools such as measurement technology www.fda.gov
5
OVRR
www.fda.gov
6
Vaccines Types •
•
• •
Inactivated/Killed Vaccines • Influenza • Polio (IPV) • Rabies Live, attenuated Vaccines • Influenza (nasal spray) • Measles, mumps, rubella (MMR combined vaccine) • Yellow fever Toxoid (inactivated toxin) Vaccines • Diphtheria, tetanus (part of DTaP combined immunization) Subunit/conjugate Vaccines • Hepatitis B • Human papillomavirus (HPV) • Pneumococcal
www.fda.gov
7
Seasonal Flu Vaccine Manufacturing Cycle Northern Hemisphere/USA
CBER
Produce Reassortants
Produce & Standardize Reagents
Annual License Approval Lot release
Select Vaccine Strain(s) WHO-FDA
Jan
Manufacturer
Dec
Feb
Mar
Apr
May
Produce Working Seeds (4 strains)
Jul
Aug
Sep
Oct
Nov
Dec
Formulation, Fill, Packaging of Vaccine
Manufacture Strain 1 Under risk Strain 2 Strain 3 Strain 4
www.fda.gov
Jun
Strain Balancing Strain Balancing Strain Balancing Strain Balancing
Distribution
8
8
Applying Advanced Manufacturing Technology to Vaccines • Modernization of vaccine production process to incorporate advanced manufacturing technologies could improve agility to respond to existing and emerging pathogens • Plans for internal research program and collaborations with federal partners initially focused on influenza vaccine – Optimize cell lines for production – Improve yield of recombinant technology – Apply continuous manufacturing www.fda.gov
9
OTAT
www.fda.gov
10
OTAT-Regulated Products •
Blood- and Plasma-derived products – – – – – – – –
•
Functionally mature/differentiated cells (e.g., retinal pigment epithelial cells, Therapeutic vaccines and other antigen-specific active immunotherapies
www.fda.gov
Gene Therapy Products – –
Coagulation factors Fibrin sealants Fibrinogen Thrombin Plasminogen Immune globulins Anti-toxins Snake venom antisera
pancreatic islets, chondrocytes, keratinocytes)
•
•
–
– –
• • •
Stem cells/stem cell-derived Products for xenotransplantation Combination products –
• •
Plasmid DNA and RNA products Viral vectors • Adeno-associated virus; Adenovirus • Retrovirus, lentivirus • Herpesvirus, vaccinia virus, fowlpox, alphavirus Bacterial vectors • E.coli • Listeria Ex vivo genetically modified cells • Transfected, transduced, electroporation Engineered nucleases for gene editing • CRISPR, TALEN, Zinc finger nucleases
Engineered tissues/organs
Devices Tissues
11 11
12
CMC expected to comply with applicable regulations
Product development should progress in parallel with clinical development Assure product quality and manufacturing consistency to support clinical studies for licensure Increasing expectation for product characterization & compliance with cGMPs Product safety, comparability to preclinical material, feasibility of process
Development
www.fda.gov
Full compliance required for licensure
Preclinical
Phase I
Phase II
Phase III
BLA
12
GT Product Approvals by FDA • Kymriah (Tisagenlecleucel) • CD19-directed genetically modified autologous T cell immunotherapy • For treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse
• Yescarta (Axicabtagene Ciloleucel) • CD19-directed genetically modified autologous T cell immunotherapy • Indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma.
• Luxturna (Voretigene Neparvovec) • adeno-associated virus vector-based gene therapy • Indicated for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy. www.fda.gov
13
www.fda.gov
14
www.fda.gov
15
Potential Challenges to Use of Cell and Gene Therapies • Process must be developed to consistently manufacture and characterize cells • Logistics of manufacturing for autologous cells can be challenging – Though an allogeneic cell line (one product) may be preferable, there are developmental challenges
www.fda.gov
16
Challenges in Manufacture of Cell and Gene Therapies • Challenges of developing and validating manufacturing processes for autologous cell therapies • Need for standards for the reproducible production of regenerative medicine products such as cellular therapies
www.fda.gov
17
Challenges in Manufacture of Cell and Gene Therapies • Lack of capacity for manufacture of lentiviral and adeno-associated virus (AAV) vectors is limiting clinical development • Process of production in current cell lines is still not able to meet demand despite some improvement over past few years
www.fda.gov
18
Improving the Manufacture of Cell and Gene Therapies • Plans for CBER laboratory research programs and collaborations with academic and public private partners to advance field – Improved cell lines for vector production – Advanced manufacturing technologies
www.fda.gov
19
Standards for Development for Human Tissues and Cellular Products • Working with National Institute of Standards and Technology (NIST) • Collaboration with the Standards Coordinating Body (outgrowth from Alliance for Regenerative Medicine) – Contract with Nexight group
• Publication of Report on the Regenerative Medicine Standards Landscape in February 2018 https://static1.squarespace.com/static/58a331b0db29d63c7fb64528/t/5ab 254f9352f5362833b9cff/1521636606100/Landscape+Report_3-2-2018.pdf
www.fda.gov
20
CBER Engagement • • • • • •
Product specific meetings Liaison meetings Standards activities International activities Collaborations Research opportunities
www.fda.gov
21
FOA: Enhancing Innovations in Emerging Technologies for Advanced Manufacturing of Complex Biologic Products (R01) • Section 3016 (Grants for Studying Continuous Manufacturing) of the 21st Century Cures Act • Support the application of novel technologies for advanced manufacturing of complex biologic products • Support innovative analytical approaches to improve product manufacturing and quality through active research • Advance innovative manufacturing by developing and making technologies accessible to industry in the near term www.fda.gov
22
The Path Toward Progress • • • •
Keep pace with advancing technology Refine regulatory framework as necessary Overcome limitations in manufacturing Facilitate optimal product development
www.fda.gov
23
Summary FDA is committed to bringing the promise of innovative, safe and effective new therapies to those in need of them, as quickly as possible.
24
Contact Information Celia Witten, Ph.D., M.D. Deputy Director Center For Biologics Evaluation And Research, FDA 10903 New Hampshire Ave Silver Spring, MD 20993 240-402-8351 celia.witten@fda.hhs.gov
25
Public Access to CBER Ø CBER website:
http://www.fda.gov/BiologicsBloodVaccines/default.htm
Ø Phone: 1-800-835-4709 Ø Consumer Affairs Branch (CAB)
Email: ocod@fda.hhs.gov Ø Manufacturers Assistance and Technical Training Branch (MATTB) Email: industry.biologics@fda.gov Ø Follow us on Twitter https://www.twitter.com/fdacber
26